In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems
Organs-on-a-Chip · 2021
DOI: 10.1016/j.ooc.2021.100010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organs-on-a-Chip, 2021. Verfasst von Xiaopeng Wen und 4 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Liaoning Revitalization Talents Program.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) is one of the common chronic liver conditions, whose treatment involves curing patients without liver transplantation. Understanding the mechanism of NAFLD initiation and progression would enable development of new diagnostic tools and drugs; however, until now, the underlying mechanisms of this condition remain largely unknown owing to the lack of experimental settings that can simplify the complicated NAFLD process in vitro . Microphysiological systems (MPSs) have long been used to recapture human pathophysiological conditions in vitro for applications in drug discovery. However, polydimethylsiloxane (PDMS) has been used in most of these MPSs as the structural material; it absorbs hydrophobic molecules, such as free fatty acids (FFAs), which are the key components that initiate NAFLD. Therefore, the current PDMS-based MPSs cannot be directly applied to in vitro NALFD modeling. In this work, we present an in vitro NAFLD model with an MPS made of cyclo-olefin polymer (COP), namely COP-MPS, to prevent absorption of FFAs. We demonstrated induction of the NAFLD-like phenotype in HepaRG hepatocyte-like cells cultured in the COP-MPS by introducing FFAs. The FFAs induced lipid accumulation in the HepaRG cells, resulting in inactivation of the apoptotic cells. We believe that the proposed COP-MPS can contribute toward investigations of NAFLD mechanisms and identification of new drugs to prevent the progression of liver disease and avoid liver transplantation.
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Liaoning Revitalization Talents Program
Zitieren
APA
Wen, X., Yoshimoto, K., Yamanaka, M., Terada, S., & Kamei, K. (2021). In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems. Organs-on-a-Chip. https://doi.org/10.1016/j.ooc.2021.100010
Vancouver
Wen X, Yoshimoto K, Yamanaka M, Terada S, Kamei K. In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems. Organs-on-a-Chip. 2021. doi:10.1016/j.ooc.2021.100010
BibTeX
@article{Wen2021,
author = {Wen, Xiaopeng and Yoshimoto, Koki and Yamanaka, Makoto and Terada, Shiho and Kamei, Ken-ichiro},
title = {In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems},
journal = {Organs-on-a-Chip},
year = {2021},
doi = {10.1016/j.ooc.2021.100010}
}
EUVIMED